Associated tags: Ozone, UV, PCO, Health, Light-emitting diode, School, Hospital, Research, Virus, University, UVC, NASA, Volatile organic compound, Infection, Jan Vansina, FDA, Allergen, HVAC, Infectious Diseases
Locations: CHINA, CALIFORNIA, DELAWARE, CARBON, NEVADA, ILLINOIS, DOMINICAN REPUBLIC, LATIN AMERICA, SPAIN, LINCOLN CENTER, MT VERNON, NY, US, SIEMENS, NO, AMERICAS, UNITED STATES, NEW YORK, SHERWIN
Retrieved on:
Wednesday, December 14, 2022
Biotechnology,
Retail,
Health,
Lodging,
Travel,
Manufacturing,
Commercial Building & Real Estate,
Luxury,
Construction & Property,
Infectious Diseases,
General Health,
Health Technology,
Other Manufacturing,
Interior Design,
Travel,
Baptist Health,
HAI,
The Related Companies,
Del Monte Foods,
FF&E,
Partnership,
Bacteria,
HEPA,
Whole Foods Market,
Allergen,
Knowledge,
Kaiser Permanente,
International Space Station,
Human,
Fenway Park,
JetBlue Park,
NASA,
Veterans' affairs,
Restaurant,
Education,
Tourism,
Cannabis,
Table,
United States Department of Veterans Affairs,
Hotel,
UV Applied UV, Inc. (NasdaqCM: AUVI) (Applied UV or the Company), a pathogen elimination technology company, announces today that its wholly owned subsidiary MunnWorks, a custom manufacturer of luxury mirrors and furniture for the hospitality market, has signed a deal to provide furnishings to three major U.S. hotels and condos.
Key Points:
- Applied UV, Inc. (NasdaqCM: AUVI) (Applied UV or the Company), a pathogen elimination technology company, announces today that its wholly owned subsidiary MunnWorks, a custom manufacturer of luxury mirrors and furniture for the hospitality market, has signed a deal to provide furnishings to three major U.S. hotels and condos.
- Applied UV also received a significant purchase order from The Related Companies , one of the largest property developers in the U.S.
- With the travel industry coming back, luxury hotels and condos are looking for opportunities to refurbish and capitalize on the increased travel demand.
- For information on Applied UV, Inc., and its subsidiaries, please visit the following websites:
Retrieved on:
Monday, December 12, 2022
Construction & Property,
Infectious Diseases,
Hospitals,
Cannabis,
Health Technology,
Building Systems,
Health,
General Health,
Natural Resources,
Security (finance),
Baptist Health,
HAI,
Acceleration,
Del Monte Foods,
Bacteria,
HEPA,
Whole Foods Market,
Allergen,
Kaiser Permanente,
International Space Station,
Fenway Park,
JetBlue Park,
NASA,
Veterans' affairs,
Education,
Pit additive,
Cannabis,
United States Department of Veterans Affairs,
Bank Applied UV, Inc. (NasdaqCM: AUVI ) (Applied UV or the Company), a pathogen elimination technology company, announces today a $5 million secured revolving credit facility effective December 8, 2022.
Key Points:
- Applied UV, Inc. (NasdaqCM: AUVI ) (Applied UV or the Company), a pathogen elimination technology company, announces today a $5 million secured revolving credit facility effective December 8, 2022.
- Borrowings under the revolving credit facility will be used for general corporate purposes and to advance Applied UVs organic and strategic growth initiatives.
- Additional details regarding the credit facility are available in a Current Report on Form 8-K filed with Securities and Exchange Commission.
- For information on Applied UV, Inc., and its subsidiaries, please visit the following websites:
Retrieved on:
Tuesday, December 6, 2022
Technology,
Medical Devices,
Infectious Diseases,
Hospitals,
Other Technology,
Cannabis,
Health Technology,
Health,
Natural Resources,
Atmosphere,
Baptist Health,
HAI,
Del Monte Foods,
Bacteria,
Sale,
HEPA,
Whole Foods Market,
Customer,
Scientific research on the International Space Station,
Allergen,
EDT,
Kaiser Permanente,
International Space Station,
Fenway Park,
JetBlue Park,
NASA,
Veterans' affairs,
Education,
Cannabis,
XL,
Tax,
Infection,
Canker,
United States Department of Veterans Affairs,
Pharmaceutical industry,
Viticulture Applied UV, Inc. (NasdaqCM:AUVI) (Applied UV or the Company), a pathogen elimination tech company that applies patented ultraviolet light (UVC) and catalytic bioconversion technology to completely destroy airborne infections and pollutants, launches Airoclean 420 40% Off Winter Sale to help the $33 billion North American cannabis market prosper.
Key Points:
- Applied UV, Inc. (NasdaqCM:AUVI) (Applied UV or the Company), a pathogen elimination tech company that applies patented ultraviolet light (UVC) and catalytic bioconversion technology to completely destroy airborne infections and pollutants, launches Airoclean 420 40% Off Winter Sale to help the $33 billion North American cannabis market prosper.
- Airoclean420 is far more effective than HEPA filters screen door design, which circulates harmful pathogens back into the air.
- Max Munn, Applied UV, Inc. President & Director said, Clean, purified air is critical to cannabis crop yield.
- *40% Off sale is applicable to the following air purification systems only: Airoclean420 MAX, Airoclean 420 XL and Airoclean 420 Home.
Retrieved on:
Tuesday, November 22, 2022
Health,
Medical Devices,
Infectious Diseases,
Technology,
Hospitals,
Health Technology,
Other Technology,
FDA,
Hospital,
NASA,
Health,
Volatile organic compound,
Infection,
Allergen,
Virus,
Light-emitting diode,
Chief Dental Officer (Canada),
Research,
Augustus A. Bird,
Acquisition,
Ozone,
PCO,
Data-driven,
UVC,
University,
School,
Pharmaceutical industry,
UV Applied UV, Inc. (NasdaqCM: AUVI ) (Applied UV or the Company), a pathogen elimination technology company that applies the power of narrow-range ultraviolet light (UVC) for surface areas and catalytic bioconversion technology for air purification to destroy pathogens safely, thoroughly, and automatically, today announced its Board of Directors has authorized the cash dividend to holders of Applied UVs 10.5% Series A Cumulative Perpetual Preferred Stock.
Key Points:
- Applied UV, Inc. (NasdaqCM: AUVI ) (Applied UV or the Company), a pathogen elimination technology company that applies the power of narrow-range ultraviolet light (UVC) for surface areas and catalytic bioconversion technology for air purification to destroy pathogens safely, thoroughly, and automatically, today announced its Board of Directors has authorized the cash dividend to holders of Applied UVs 10.5% Series A Cumulative Perpetual Preferred Stock.
- Holders of the 10.5% Series A Cumulative Perpetual Preferred Stock (Nasdaq: AUVIP) shall receive a cash dividend equal to $0.21875 per share.
- Applied UV is focused on the development and acquisition of technology that address infection control in the healthcare, hospitality, commercial and municipal markets.
- For more information about Applied UV, Inc., and its subsidiaries, please visit the following websites: https://www.applieduvinc.com/ ; https://sterilumen.com/ ; https://www.airocide.com https://kesscience.com ; https://scientificairmanagement.com and, https://munnworks.com/ .
Retrieved on:
Monday, November 14, 2022
Communications,
Medical Devices,
Health,
Health Technology,
General Health,
Public Relations,
Investor Relations,
Data-driven,
Company,
Augustus A. Bird,
Virus,
Research,
LLC,
Light-emitting diode,
Hospital,
Allergen,
NASA,
FDA,
Volatile organic compound,
Infection,
Center for Food Safety and Applied Nutrition,
UVC,
University,
Health,
PCO,
School,
Investor relations,
Acquisition,
Ozone,
Chief Dental Officer (Canada),
Technology,
Eyeish,
Pharmaceutical industry,
UV Applied UV's management team will host an investor conference call and live webcast on November 15, 2022, at 9:00 am ET.
Key Points:
- Applied UV's management team will host an investor conference call and live webcast on November 15, 2022, at 9:00 am ET.
- Investors can access the live webcast via a link on Applied UV's web site or at https://www.webcaster4.com/Webcast/Page/2626/47024 .
- For those planning to participate on the call, please dial +1-877-545-0523 (for domestic calls), or +1-973-528-0016 (for international calls), passcode 583604.
- Applied UV is focused on the development and acquisition of technology that address infection control in the healthcare, hospitality, commercial and municipal markets.
Retrieved on:
Tuesday, November 1, 2022
Medical Devices,
Health,
Technology,
Infectious Diseases,
Other Technology,
Health Technology,
Volatile organic compound,
Eyeish,
Augustus A. Bird,
School,
Acquisition,
Partnership,
Research,
Virus,
LLC,
Industry,
Hospital,
PCO,
R,
Health,
Pinnacle Bank Arena,
Technology,
University,
Documentation,
Ozone,
Chief Dental Officer (Canada),
Company,
Light-emitting diode,
FDA,
Allergen,
NASA,
Infection,
Note,
UVC,
Solution,
Data-driven,
Pharmaceutical industry,
UV This additional capital is expected to be used to support the Companys growth initiatives.
Key Points:
- This additional capital is expected to be used to support the Companys growth initiatives.
- On October 7, 2022, Applied UV entered a securities purchase agreement whereby a single investor purchased an 18 month $2,807,500 Redeemable Note from the Company for $2,500,000.
- Applied UV is focused on the development and acquisition of technology that address infection control in the healthcare, hospitality, commercial and municipal markets.
- For more information about Applied UV, Inc., and its subsidiaries, please visit the following websites: https://www.applieduvinc.com
The information contained herein may contain forwardlooking statements.
Biotechnology,
Medical Devices,
Infectious Diseases,
Health,
Health Technology,
Health,
Augustus A. Bird,
Virus,
NASA,
LLC,
Hospital,
Research,
Chief Dental Officer (Canada),
Volatile organic compound,
Allergen,
Nasdaq,
Technology,
University,
Company,
Acquisition,
PCO,
Board,
Data-driven,
Ozone,
Light-emitting diode,
Infection,
Board of directors,
UVC,
FDA,
School,
Pharmaceutical industry,
UV Applied UV, Inc. (NasdaqCM: AUVI ) (Applied UV or the Company), a pathogen elimination technology company that applies the power of narrow-range ultraviolet light (UVC) for surface areas and catalytic bioconversion technology for air purification to destroy pathogens safely, thoroughly, and automatically, today announced its Board of Directors has authorized the cash dividend to holders of Applied UVs 10.5% Series A Cumulative Perpetual Preferred Stock.
Key Points:
- Applied UV, Inc. (NasdaqCM: AUVI ) (Applied UV or the Company), a pathogen elimination technology company that applies the power of narrow-range ultraviolet light (UVC) for surface areas and catalytic bioconversion technology for air purification to destroy pathogens safely, thoroughly, and automatically, today announced its Board of Directors has authorized the cash dividend to holders of Applied UVs 10.5% Series A Cumulative Perpetual Preferred Stock.
- Holders of the 10.5% Series A Cumulative Perpetual Preferred Stock (Nasdaq: AUVIP) shall receive a cash dividend equal to $0.21875 per share.
- Applied UV is focused on the development and acquisition of technology that address infection control in the healthcare, hospitality, commercial and municipal markets.
- For more information about Applied UV, Inc., and its subsidiaries, please visit the following websites: https://www.applieduvinc.com/ ; https://sterilumen.com/ ; https://www.airocide.com ; https://kesscience.com ; https://scientificairmanagement.com and, https://munnworks.com/ .
